SCHEMBL6965243

SCHEMBL6965243

CC(C)c1ccc(C(C)C)c(Sc2c(O)cc(-c3ccccc3)oc2=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TNKS O95271 1/20 0.41
PARP1 P09874 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PARP2 Q9UGN5 1/20 0.41
ABCB1 P08183 5/20 0.40
MGAM O43451 2/20 0.40
GAA P10253 2/20 0.40
SI P14410 2/20 0.40
MGAM2 Q2M2H8 2/20 0.40
HTT P42858 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PTGES O14684 1/20 0.35
HSP90AA1 P07900 1/20 0.35
MAPT P10636 3/20 0.35
ALOX15 P16050 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6953776 0.98 TNKS (0.42) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6953773 0.93 SMN1; SMN2 (0.37) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6953779 0.91 GPR35 (0.36) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6961039 0.90 SMN1; SMN2 (0.46) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6960410 0.88 POLB (0.42) SMN1; SMN2POLBL3MBTL1ABCB1MGAM
SCHEMBL6955834 0.87 SMN1; SMN2 (0.39) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6957519 0.85 SMN1; SMN2 (0.38) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6959051 0.85 ABCB1 (0.43) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6959070 0.84 POLB (0.42) SMN1; SMN2POLBL3MBTL1TNKSPARP1
SCHEMBL6963494 0.83 PTGES (0.43) SMN1; SMN2POLBL3MBTL1TNKSPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed